Study: Patients with Deductibles and Coinsurance Pay More When a Drug’s List Price Rises

A new study in JAMA Open Network found that, when brand drug manufacturers raise their list prices, commercially insured patients with deductibles and coinsurance do not directly benefit from the secret rebates the manufacturers pay insurance companies and PBMs. | Shutterstock
Commercially insured patients with deductibles and coinsurance pay more when manufacturers raise a drug’s list price and do not directly benefit from the confidential rebates paid by manufacturers to insurers, according to a study published this morning in JAMA Open
Read More »

Kalderos: 3-5% of 340B Discounts and Medicaid Rebates Are Duplicates

Drug industry vendor Kalderos says duplicate 340B discounts and Medicaid rebates cost the industry between $933 million and $1.6 billion in 2019.
Between 3% and 5% of 340B drug discounts and Medicaid drug rebates are duplicates, adding up to at least $933 million and potentially as high as $1.6 billion in additional costs to the pharmaceutical industry in 2019, according to new
Read More »

CBO Report: R&D Costs Do Not Influence Pharma Pricing

A prescription drug's sunk R&D costs do not influence the drug's price, the Congressional Budget Office found.
The pharmaceutical industry’s spending on research and development as a proportion of its revenue dwarfs virtually all other manufacturing sectors, but those costs do not really impact pricing, according to a new analysis by the Congressional Budget Office.
Read More »

Pharma’s Plans to Rebuild Health Care Include Overhauling 340B

New reports from drugmaker Janssen (left) and PhRMA recommend taking 340B drug discounts away from hospitals and contract pharmacies and giving them to patients.
New reports from pharmacy giant Janssen and Pharmaceutical Research and Manufacturers of America (PhRMA) suggest that the pharma sector could be making the 340B program an even bigger target than it has been in recent years.
Read More »

340B Sales Grew 18% from 2019 to 2020, Drug Industry Consulting Firm Says

Growth in 340B sales is being driven by specialty products and use of mail-order contract pharmacy, pharmacy consulting firm IQVIA says.
Drug industry consulting and contract research firm IQVIA reports that prescription drug sales at 340B-discounted prices grew 18.1% year-on-year from 2019 to 2020.

Please Login or Become a Paid Subscriber to View this Content

Read More »

340B Hospitals More Likely to Make Medicine More Accessible, Study Finds

University of Illinois Chicago researchers found that 340B hospitals provide significantly more medication access services such as discharge prescriptions to patients at bedside than comparably sized non-340B hospitals. | Shutterstock
340B hospitals provide “a significantly higher average number” of medication access (MA) services—such as free or discounted drugs or free delivery—than comparably sized non-340B hospitals, a new academic study shows.

Please Login or Become a Paid

Read More »

Study in Health Affairs Could Reignite Debate Over Some 340B Hospitals Charity Care

Researchers at The Johns Hopkins University found that nonprofit hospitals spend significantly less on charity care than government or for-profit hospitals.
A study published online by Health Affairs yesterday focused on nonprofit hospitals’ provision of charity care could renew drug manufacturers’ calls for more control over those hospitals’ participation in the 340B program.

Please Login or Become

Read More »

Survey: Pharma’s 340B Contract Pharmacy Actions are Putting the Squeeze on Hospitals

Nearly all (97 percent) of all 340B hospitals in a recent survey said they are impacted by drug manufacturers' curbs on contract pharmacy use. | Shutterstock
340B hospitals are under significant pressure due to drug manufacturers ending 340B discounts on drugs dispensed by contract pharmacies, hospital advocacy group 340B Health says in its latest annual member survey.

Please Login or Become a

Read More »

Medicare’s 340B Drug Reimbursement Cuts in 2019 Were Exacerbated by Change in Drugs’ Payment Status

A change in Medicare Part B payment status for "an unusually high" number of drugs in 2019 led to "substantially" lower payments to 340B hospitals, congressional Medicare advisers said this week.
Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday.

Please Login

Read More »

Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption

Humira, one of the 15 partial orphan drugs examined in the new study in Health Affairs, had $13.7 billion in sales in 2018.
More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes. Policymakers who “wish to decrease
Read More »
Generic selectors
Exact matches only
Search in title
Search in content

Sign up for news summaries and alerts from 340B Report